# CarbGen Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/carbgen-co

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.carbgem.com
- Total disclosed funding: $3.4M
- Latest round: Series A (Jan 16, 2023)
- Investors on record: 1

## About

Established in 2021 and based in Tokyo, Japan, CarbGen Co., Ltd. operates as a biotechnology company that engages in the research and development of bacterial infectious diseases and drug resistance through bioinformatics and artificial technology. As of January 2023, Masakazu Nakajima serves as the CEO of the company. In January 2023, CarbGen Co., Ltd. raised Series A financing from UB Ventures.

The company provides products and services including point-of-care automatic Gram dyeing machines (POCGS); BiTTE, an app that aids in the selection of antibacterial medications by estimating the species of bacterial infections; medical image remote diagnosis support platform (CB Connect); microorganism observation smartphone adapter (AMO); specialised field consulting in infectious disease areas and business planning support services; and support services for specialists in infectious diseases and drug resistance issues.

The business offers technology like the CBX-030A bacterial estimation and antibiotic suggestion system, the CBX-047A telediagnostic platform for medical images, the CBX-049A point-of-care gram stainer, and the CBX-048 adapter for microscopic inspection. CarbGen’s partners include Kobe University, Northwell Health Foundation, NCGM, and others.

The organization plans to use the January 2023 funding for product development, marketing, and recruitment.

## Funding rounds

- Series A, Jan 16, 2023, $3.4M — FIRSTLIGHT Capital

## Investors

- FIRSTLIGHT Capital — Series A